Clinical Trials | December 09, 2025
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
HYMPAVZI’s safety profile was generally favorable
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Subscribe To Our Newsletter & Stay Updated
